8-K: Fennec Pharma Initiates New Study for PEDMARK in Cancer Patients

Fennec Pharmaceuticals announced the initiation of an investigator-sponsored study by the University of Arizona Cancer Center to evaluate PEDMARK's use in adult patients with head and neck and testicular cancers receiving cisplatin.

Summary

• Fennec Pharmaceuticals Inc. has announced the initiation of an investigator-sponsored study by the University of Arizona Cancer Center.
• This study will evaluate the use of PEDMARK (sodium thiosulfate injection) in adolescent and young adult (AYA) and adult patients diagnosed with head and neck and testicular cancers who are undergoing cisplatin treatment.
• PEDMARK is currently approved for pediatric patients aged one month and older with localized, non-metastatic solid tumors and is recommended by the National Comprehensive Cancer Network (NCCN) for AYA patients.
• This initiative is part of ongoing independent research to expand the real-world validation of PEDMARK across new tumor types and patient populations.
• The study aims to determine the efficacy of PEDMARK in reducing cisplatin-induced hearing loss and to analyze the systemic elimination of unbound cisplatin.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating continued research and potential market expansion for PEDMARK, although it is an early-stage investigator-sponsored study.

Positives

• Initiation of a new investigator-sponsored study by a reputable cancer center (University of Arizona Cancer Center) to evaluate PEDMARK in a new patient population (AYA and adult head and neck and testicular cancer patients).
• This study contributes to the growing body of real-world evidence supporting PEDMARK's potential to prevent ototoxicity in a broader patient demographic.
• The study aligns with Fennec's commitment to supporting independent research that expands the understanding and clinical adoption of PEDMARK.
• PEDMARK is already approved for pediatric patients and recommended by NCCN for AYA patients, indicating existing clinical acceptance.
• Recent announcements of other institution-led studies (Tampa General Hospital, City of Hope) further demonstrate ongoing research and validation efforts.

Negatives

• The study is investigator-sponsored, meaning Fennec does not directly control the research, though they support it.
• The efficacy and safety of PEDMARK have not been established for cisplatin infusions longer than 6 hours, as irreversible ototoxicity may have already occurred.
• Potential for hypersensitivity reactions (8-13% in trials), hypernatremia (12-26%), and hypokalemia (15-27%) are noted safety concerns.
• The study is in its early stages (Phase I/II), and results are not yet available.
• The NCCN recommendation for AYA patients is a 2A, which is a lower level of evidence compared to higher recommendations.

Risks

• The potential for regulatory authorities to not approve label expansion for PEDMARK into these new patient populations, even with positive study data.
• The risk that the study results may not be replicated in actual patient settings or may not demonstrate a statistically significant benefit.
• Competition from other potential otoprotective agents or alternative treatment strategies for cisplatin-induced ototoxicity.
• Challenges in obtaining necessary capital for continued research, development, and commercialization efforts.
• Potential for patent challenges, invalidation, or circumvention by competitors.
• Unforeseen global instability, including political instability or pandemics, could impact research timelines and commercialization.
• The market for PEDMARK may not be as large as expected, or the product may not penetrate targeted markets effectively.
• The company may not meet its future capital requirements.

Future Outlook

The company anticipates continued dialogue with regulatory authorities regarding potential pathways for PEDMARK label expansion as more evidence-based data matures. Future commercial and regulatory milestones, along with royalty payments from Norgine, are expected.

Management Comments

• "At Fennec, we are committed to supporting independent research efforts, which help build real-world evidence and expand understanding of how PEDMARK may benefit patients beyond the populations studied in our pivotal trials."
• "Within the last few months, we have announced the initiation of three new studies with leading and highly respected academic and community oncology centers."
• "We believe that data and insights generated through these studies and others to come will help support broader clinical adoption of PEDMARK to prevent ototoxicity, or permanent hearing loss, in AYA and adult cancer patients receiving cisplatin-based treatment."
• "We look forward to continued dialogue with regulatory authorities regarding the potential pathways for PEDMARK label expansion as our growing body of evidence-based data matures."

Industry Context

StockSavvy.ai notes that Fennec Pharmaceuticals is actively pursuing label expansion for its ototoxicity drug, PEDMARK, by supporting investigator-initiated studies. This strategy is common in the pharmaceutical industry to generate real-world evidence and explore new indications, potentially broadening market access and revenue streams. The focus on AYA and adult cancer patients receiving cisplatin aligns with efforts to address unmet needs in cancer survivorship care.

Stakeholder Impact

• Shareholders: Potential for increased future revenue and market share if PEDMARK gains label expansion for new indications.
• Patients: Potential for reduced risk of permanent hearing loss (ototoxicity) from cisplatin chemotherapy, improving quality of life.
• Healthcare Providers: Provides an additional tool to manage a significant side effect of a critical cancer treatment.
• Regulatory Authorities: Will review data from new studies to determine potential label expansions.

Next Steps

• Conducting the Phase I/II Open-Label Trial of Intravenous Sodium Thiosulfate (PEDMARK) as Otoprotectant in Adults Receiving Cisplatin Chemotherapy at the University of Arizona Cancer Center.
• Continuing to review additional investigator-initiated studies submitted to Fennec.
• Engaging in dialogue with regulatory authorities regarding potential label expansion for PEDMARK.
• Commercializing PEDMARQSI in Europe, UK, Australia, and New Zealand through Norgine Pharmaceuticals Ltd.

Key Dates

Recommendation

The filing announces the initiation of an investigator-sponsored study, which is a positive step for potential future label expansion of PEDMARK. However, it does not contain immediate financial results or significant strategic shifts that would warrant a strong buy or sell recommendation. The company's commercialization efforts are ongoing, but the impact of this specific study is long-term and uncertain. Therefore, a 'hold' recommendation is appropriate pending further results and strategic developments.

Keywords

PEDMARK, Fennec Pharmaceuticals, Ototoxicity, Cisplatin, Cancer Treatment, Investigator-Sponsored Study, University of Arizona Cancer Center, Sodium Thiosulfate